Bottom line
CURE vs TYO: the short answer
CURE (Direxion Daily Healthcare Bull 3X ETF) and TYO (Direxion Daily 7-10 Year Treasury Bear 3X ETF) are both etfs.
But CURE is far broader, holding 67 positions to 6 for TYO, so beyond the top names it adds exposure TYO doesn't have.
CURE is cheaper at 0.94% vs 1% — a difference of $6.00 a year per $10,000 invested.
Over five years, TYO returned +13.2% a year vs +8.6% for CURE.
Updated Nov 19, 2026
CURE vs TYO side by side
| CURE | TYO | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.94% | 1% |
| Annual cost per $10k | $94 | $100 |
| 10-yr cost on $10k (prospectus) | $1,155 | $1,384 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +22.9% | −7.7% |
| 5-yr return (annualized) | +8.6% | +13.2% |
| 10-yr return (annualized) | +13.6% | −0.9% |
| Best quarter | +46.9% | +19.8% |
| Worst quarter | −45.8% | −26.8% |
| Net assets (fund) | $171.7M | $12.5M |
| Number of holdings | 67 | 6 |
| Portfolio turnover | 1% | % |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | CURE | TYO | Difference |
|---|---|---|---|
| 2025 | +22.9% | −7.7% | +30.6% |
| 2024 | −8.5% | +18.9% | −27.4% |
| 2023 | −9.8% | +0.7% | −10.4% |
| 2022 | −20.4% | +59.4% | −79.8% |
| 2021 | +87.4% | +5.6% | +81.8% |
| 2020 | +5.1% | −27.5% | +32.6% |
| 2019 | +55.9% | −18.6% | +74.4% |
| 2018 | +2.9% | −0.9% | +3.8% |
| 2017 | +69.3% | −9.3% | +78.5% |
| 2016 | −17.4% | −7.7% | −9.8% |
Source: Fund prospectus bar charts
Holdings overlap
6 of CURE's top 25 holdings also appear in TYO's top 6.
| Holding | CURE | TYO |
|---|---|---|
| Dreyfus | 18.79% | 62.27% |
| N/a | 8.28% | 2.50% |
| Goldman Sachs Liq Es Fd A | 8.19% | 16.61% |
| Goldman Financial | 7.51% | 18.94% |
| N/a | 3.34% | 2.50% |
| N/a | 1.12% | 2.50% |
Source: SEC Form N-PORT
CURE top 10
- Dreyfus — 18.79%
- Eli Lilly & Company — 10.41%
- N/a — 8.28%
- Goldman Sachs Liq Es Fd A — 8.19%
- Goldman Financial — 7.51%
- Johnson & Johnson — 7.07%
- Abbvie Inc — 5.08%
- Unitedhealth Group Inc — 4.31%
- Merck & Company Inc — 3.68%
- N/a — 3.34%
TYO top 10
- Dreyfus — 62.27%
- Goldman Financial — 18.94%
- Goldman Sachs Liq Es Fd A — 16.61%
- N/a — 5.21%
- N/a — 2.70%
- N/a — 2.50%
FAQ
What is the difference between CURE and TYO?
Which is cheaper, CURE or TYO?
Should I own both CURE and TYO?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.